Abstract
Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have